These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30207078)

  • 1. Toxoplasmosis and secondary Guillain-Barré associated with ruxolitinib as graft-versus-host disease treatment.
    Gonzalez Vicent M; Molina B; Fabregat M; Segura M; Diaz MA
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27446. PubMed ID: 30207078
    [No Abstract]   [Full Text] [Related]  

  • 2. [Guillain-Barre syndrome after allogeneic hematopoietic stem cell transplantation: a case report and literature review].
    Shi YJ; Han Y; Wang Y; Zhou R; Song R; Mao DF; Xi R; Bai H; Wu T
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):509-511. PubMed ID: 38964928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guillain-Barré syndrome after transplantation.
    Zhang L; Arrington S; Keung YK
    Leuk Lymphoma; 2008 Feb; 49(2):291-7. PubMed ID: 18231916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guillain-Barré syndrome after human herpesvirus-6 reactivation in unrelated hematopoietic stem cell transplantation.
    Piras E; Caocci G; Pisano V; Orrù F; Murgia F; Sanna M; Vacca A; La Nasa G
    Leuk Lymphoma; 2013 Jun; 54(6):1332-3. PubMed ID: 23088724
    [No Abstract]   [Full Text] [Related]  

  • 5. Guillain-Barré syndrome associated with cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Hernández-Boluda JC; Lis MJ; Goterris R; Arbona C; Terol MJ; Tormo M; Solano C
    Transpl Infect Dis; 2005 Jun; 7(2):93-6. PubMed ID: 16150099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation.
    Rodriguez V; Kuehnle I; Heslop HE; Khan S; Krance RA
    Bone Marrow Transplant; 2002 Mar; 29(6):515-7. PubMed ID: 11960272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guillain-Barré syndrome after autologous peripheral blood stem cell transplantation for CML.
    Janssen JJ; Tissingh G; Ossenkoppele GJ
    Eur J Haematol; 1999 Nov; 63(5):358-9. PubMed ID: 10580569
    [No Abstract]   [Full Text] [Related]  

  • 8. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
    Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral toxoplasmosis and Guillain-Barré syndrome after allogeneic peripheral stem cell transplantation.
    González MI; Caballero D; López C; Alburquerque T; Hernández R; de la Loma A; Cañizo C; Vázquez L; San Miguel JF
    Transpl Infect Dis; 2000 Sep; 2(3):145-9. PubMed ID: 11429026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Guillain-Barre syndrome after allogeneic hematopoietic stem cell transplantation: two cases report and literature review].
    Xu X; Jia L; Chen L; Zhang W; Wang J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):694-7. PubMed ID: 25152114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxoplasmosis disease in paediatric hematopoietic stem cell transplantation: do not forget it still exists.
    Decembrino N; Comelli A; Genco F; Vitullo A; Recupero S; Zecca M; Meroni V
    Bone Marrow Transplant; 2017 Sep; 52(9):1326-1329. PubMed ID: 28604668
    [No Abstract]   [Full Text] [Related]  

  • 12. Guillain-Barre syndrome--pathological connection with GvHD after allogeneic bone marrow transplantation.
    Nasilowska-Adamska B; Lysiak Z; Halaburda K; Szczepinski A; Ejduk A; Marianska B
    Ann Transplant; 2006; 11(3):10-1. PubMed ID: 17494293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis.
    Shahnaz Syed Abd Kadir S; Christopeit M; Wulf G; Wagner E; Bornhauser M; Schroeder T; Crysandt M; Mayer K; Jonas J; Stelljes M; Badbaran A; Ayuketang Ayuk F; Triviai I; Wolf D; Wolschke C; Kröger N
    Eur J Haematol; 2018 Sep; 101(3):305-317. PubMed ID: 29791053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-responsive Guillain-Barré syndrome following allogeneic hematopoietic SCT.
    Ostronoff F; Perales MA; Stubblefield MD; Hsu KC
    Bone Marrow Transplant; 2008 Jul; 42(1):71-2. PubMed ID: 18391992
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report.
    Hughes CL; Yorio JT; Kovitz C; Oki Y
    J Med Case Rep; 2014 Dec; 8():455. PubMed ID: 25528252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D
    Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guillain-Barré syndrome as leading manifestation of graft-versus-host disease in an allogeneic bone marrow transplanted patient.
    Thöne J; Lamprecht S; Hohaus A; Erbguth F; Bickel A
    J Neurol Sci; 2010 May; 292(1-2):114-6. PubMed ID: 20163810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive treatment of severe acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Zupan IP; Zver S; Pretnar J
    Transplant Proc; 2002 Nov; 34(7):2931-3. PubMed ID: 12431662
    [No Abstract]   [Full Text] [Related]  

  • 19. Flavivirus cross-reactivity in serological tests and Guillain-Barré syndrome in a hematopoietic stem cell transplant patient: A case report.
    Raboni SM; Bonfim C; Almeida BM; Zanluca C; Koishi AC; Rodrigues PRVP; Kay CK; Ribeiro LL; Scola RH; Duarte Dos Santos CN
    Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28306183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.